According to MSD China, on September 29, MSD announced that the subcutaneous dosage form of its PD-1 inhibitor pabolizumab injection has been approved by the China National Drug Administration, covering 19 solid tumor indications, making it the first and currently the only PD-1 inhibitor approved for subcutaneous injections in China.

Zhitongcaijing · 2d ago
According to MSD China, on September 29, MSD announced that the subcutaneous dosage form of its PD-1 inhibitor pabolizumab injection has been approved by the China National Drug Administration, covering 19 solid tumor indications, making it the first and currently the only PD-1 inhibitor approved for subcutaneous injections in China.